Cytokinetics Incorporated Common Stock (CYTK)

About CYTK

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

673

Website

cytokinetics.com/

Fundamentals

1-day range

$75.87$81.37

Market cap

$10.13B

P/E (trailing)

—

P/E (forward)

-17.10

EPS (trailing)

$-7.22

Dividend yield

—

Beta

0.35

Avg. volume

2.15M

Forecasts

20 analyst ratings

Cytokinetics Incorporated Common Stock Competitors

Chosen by industry and closest market cap.

• CYTK

  Cytokinetics Incorporated Common Stock

  $72.17

  ▼ 7.36%
  Market cap $10.13BP/E —
  $35.22$88.31
• PRAX

  Praxis Precision Medicines Inc. Common Stock

  $344.95

  ▼ 6.23%
  Market cap $10.32BP/E —
  $37.19$392.7
• SMMT

  Summit Therapeutics Inc. Common Stock

  $13.71

  ▼ 4.33%
  Market cap $10.80BP/E —
  $12.07$29.23
• AXSM

  Axsome Therapeutics Inc. Common Stock

  $199.01

  ▼ 3.52%
  Market cap $10.81BP/E —
  $112.9$260.19
• PTGX

  Protagonist Therapeutics Inc. Common Stock

  $144.15

  ▼ 3.58%
  Market cap $9.40BP/E 119.77
  $54.5$160.81
• SYRE

  Spyre Therapeutics Inc. Common Stock

  $90.4

  ▼ 3.43%
  Market cap $9.12BP/E —
  $14.51$110.18
• ABVX

  Abivax SA American Depositary Shares

  $113.41

  ▼ 0.78%
  Market cap $11.19BP/E —
  $60.45$139

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today
  benzinga · 8/28/2026
• Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Aficamten in Nonobstructive HCM Transcript
  SeekingAlpha · 8/28/2026
• If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today
  Benzinga · 8/28/2026
• Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700
  Yahoo · 8/22/2026
• Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
  Yahoo · 8/20/2026
• Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
  Yahoo · 8/19/2026
• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Yahoo · 8/18/2026
• Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
  Yahoo · 8/14/2026
• Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript
  Yahoo · 8/13/2026

• Andrew Callos · July 30, 2026 · Option Exercise

  14.0K @ $23.26
• Andrew Callos · July 30, 2026 · Sale

  14.0K @ $79.88
• Fady Ibraham Malik · July 21, 2026 · Option Exercise

  3.5K @ $7.8
• Fady Ibraham Malik · July 21, 2026 · Sale

  3.5K @ $80.59
• Nancy Wysenski · July 15, 2026 · Grant

  75 @ $82.62
• Wendell Wierenga · July 15, 2026 · Grant

  75 @ $82.62
• Edward M. Kaye, MD · July 15, 2026 · Grant

  151 @ $82.62
• John T. Henderson · July 15, 2026 · Grant

  272 @ $82.62
• Robert Arthur Harrington · July 15, 2026 · Grant

  151 @ $82.62
• James M. Daly · July 15, 2026 · Grant

  151 @ $82.62
• Robert I. Blum · July 13, 2026 · Option Exercise

  7.5K @ $10.6
• Robert I. Blum · July 13, 2026 · Sale

  7.5K @ $82.02
• Robert I. Blum · July 13, 2026 · Sale

  10 @ $82.02
• Fady Ibraham Malik · July 7, 2026 · Option Exercise

  3.5K @ $7.8
• Fady Ibraham Malik · July 7, 2026 · Sale

  3.5K @ $86.62

Institutional Ownership

March 31, 2026

Total shares held

148.78M

Total value held

$8.46B

Institutional holders

438